The PCSK9 antibodies evolocumab and alirocumab target the PCSK9 enzyme in plasma and were the first biologics approved for heterozygous familial hypercholesterolemia (HeFH), as well as for resistant hyperlipidemias [22]. The gene discussed is PCSK9; the disease is hyperlipidemia.